Mottola Frank — SEC Form 4 filings
SEC reporting owner CIK 1804567. 22 Form 4 filings on record with FilingPulse; latest filed 2026-08-14.
Transaction summary — filings shown
Covers all 22 filings on record, filed 2024-02-26 to 2026-08-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 6 legs across 5 filings — 55,623 shares, $2,502,414 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 71.
- Largest priced transaction: sale of 15,000 shares @ $50.47 ($757,050) in SUPERNUS PHARMACEUTICALS, INC., filed 2025-12-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | SVP, Chief Tech. Ops. Officer | 22 | — | 6 legs · 55,623 sh · $2,502,414 | 71 |
Form 4 filings — Mottola Frank
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-14 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 1,650 @ $0 · Tax withholding (F): 797 @ $46.57 · Option exercise (M): 1,650 (derivative) @ $0 | EDGAR |
| 2026-07-31 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 1,650 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 3,750 @ $0 · Tax withholding (F): 1,793 @ $54.73 · Sale (S): 1,623 @ $53.65 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 3,750 (derivative) @ $0 | EDGAR |
| 2026-02-26 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 1,875 @ $0 · Tax withholding (F): 977 @ $50.69 · Disposition to issuer (D): 1,875 (derivative) @ $0 | EDGAR |
| 2026-02-25 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 1,125 @ $0 · Tax withholding (F): 603 @ $51.35 · Grant/award (A): 750 @ $0 · Tax withholding (F): 368 @ $50.86 · Grant/award (A): 1,250 @ $0 · Tax withholding (F): 670 @ $50.86 · +3 more | EDGAR |
| 2026-02-20 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 13,500 (derivative) @ $0 · Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2025-12-22 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 5,000 @ $39.40 · Sale (S): 5,000 @ $50.22 · Option exercise (M): 15,000 @ $25.30 · Sale (S): 15,000 @ $50.47 · Option exercise (M): 5,000 (derivative) @ $0 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2025-09-15 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 5,000 @ $39.40 · Sale (S): 5,000 @ $45.87 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 14,000 @ $12.98 · Sale (S): 14,000 @ $44.51 · Option exercise (M): 14,000 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 2,625 @ $0 · Tax withholding (F): 1,356 @ $39.11 · Option exercise (M): 2,625 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Tax withholding (F): 337 @ $33.05 · Tax withholding (F): 610 @ $33.05 · Tax withholding (F): 945 @ $33.05 | EDGAR |
| 2025-02-26 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 2,010 @ $0 · Tax withholding (F): 976 @ $39.48 · Option exercise (M): 3,750 @ $0 · Tax withholding (F): 1,909 @ $39.48 · Option exercise (M): 2,010 (derivative) @ $0 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2025-02-24 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 1,125 @ $0 · Tax withholding (F): 552 @ $39.15 · Grant/award (A): 750 @ $0 · Grant/award (A): 1,250 @ $0 · Grant/award (A): 1,875 @ $0 · Option exercise (M): 1,125 (derivative) @ $0 · +3 more | EDGAR |
| 2025-02-21 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 20,000 (derivative) @ $0 · Grant/award (A): 4,500 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 2,625 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 3,750 (derivative) @ $0 · Grant/award (A): 2,010 (derivative) @ $0 | EDGAR |
| 2025-01-29 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 1,125 (derivative) @ $0 | EDGAR |
| 2024-11-08 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 15,000 @ $9.13 · Sale (S): 15,000 @ $36.98 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2024-02-29 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Option exercise (M): 990 @ $0 · Tax withholding (F): 460 @ $27.94 · Option exercise (M): 990 (derivative) @ $0 | EDGAR |
| 2024-02-27 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 1,875 @ $0 · Tax withholding (F): 937 @ $29.06 · Disposition to issuer (D): 1,875 (derivative) @ $0 | EDGAR |
| 2024-02-26 | 4 | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | Grant/award (A): 750 @ $0 · Tax withholding (F): 335 @ $27.94 · Disposition to issuer (D): 750 (derivative) @ $0 · Grant/award (A): 5,000 (derivative) @ $0 · Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 990 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1804567 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →